Cargando…
Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction
Background and Aim: Tacrolimus (TAC) is a first-line immunosuppressant for the treatment of refractory nephrotic syndrome (RNS), but the pharmacokinetics of TAC varies widely among individuals, and there is still no accurate model to predict the pharmacokinetics of TAC in RNS. Therefore, this study...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706003/ https://www.ncbi.nlm.nih.gov/pubmed/36457704 http://dx.doi.org/10.3389/fphar.2022.942129 |
_version_ | 1784840412492464128 |
---|---|
author | Huang, Qiongbo Lin, Xiaobin Wang, Yang Chen, Xiujuan Zheng, Wei Zhong, Xiaoli Shang, Dewei Huang, Min Gao, Xia Deng, Hui Li, Jiali Zeng, Fangling Mo, Xiaolan |
author_facet | Huang, Qiongbo Lin, Xiaobin Wang, Yang Chen, Xiujuan Zheng, Wei Zhong, Xiaoli Shang, Dewei Huang, Min Gao, Xia Deng, Hui Li, Jiali Zeng, Fangling Mo, Xiaolan |
author_sort | Huang, Qiongbo |
collection | PubMed |
description | Background and Aim: Tacrolimus (TAC) is a first-line immunosuppressant for the treatment of refractory nephrotic syndrome (RNS), but the pharmacokinetics of TAC varies widely among individuals, and there is still no accurate model to predict the pharmacokinetics of TAC in RNS. Therefore, this study aimed to combine population pharmacokinetic (PPK) model and machine learning algorithms to develop a simple and accurate prediction model for TAC. Methods: 139 children with RNS from August 2013 to December 2018 were included, and blood samples of TAC trough and partial peak concentrations were collected. The blood concentration of TAC was determined by enzyme immunoassay; CYP3A5 was genotyped by polymerase chain reaction-restriction fragment length polymorphism method; MYH9, LAMB2, ACTN4 and other genotypes were determined by MALDI-TOF MS method; PPK model was established by nonlinear mixed-effects method. Based on this, six machine learning algorithms, including eXtreme Gradient Boosting (XGBoost), Random Forest (RF), Extra-Trees, Gradient Boosting Decision Tree (GBDT), Adaptive boosting (AdaBoost) and Lasso, were used to establish the machine learning model of TAC clearance. Results: A one-compartment model of first-order absorption and elimination adequately described the pharmacokinetics of TAC. Age, co-administration of Wuzhi capsules, CYP3A5 *3/*3 genotype and CTLA4 rs4553808 genotype were significantly affecting the clearance of TAC. Among the six machine learning models, the Lasso algorithm model performed the best (R(2) = 0.42). Conclusion: For the first time, a clearance prediction model of TAC in pediatric patients with RNS was established using PPK combined with machine learning, by which the individual clearance of TAC can be predicted more accurately, and the initial dose of administration can be optimized to achieve the goal of individualized treatment. |
format | Online Article Text |
id | pubmed-9706003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97060032022-11-30 Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction Huang, Qiongbo Lin, Xiaobin Wang, Yang Chen, Xiujuan Zheng, Wei Zhong, Xiaoli Shang, Dewei Huang, Min Gao, Xia Deng, Hui Li, Jiali Zeng, Fangling Mo, Xiaolan Front Pharmacol Pharmacology Background and Aim: Tacrolimus (TAC) is a first-line immunosuppressant for the treatment of refractory nephrotic syndrome (RNS), but the pharmacokinetics of TAC varies widely among individuals, and there is still no accurate model to predict the pharmacokinetics of TAC in RNS. Therefore, this study aimed to combine population pharmacokinetic (PPK) model and machine learning algorithms to develop a simple and accurate prediction model for TAC. Methods: 139 children with RNS from August 2013 to December 2018 were included, and blood samples of TAC trough and partial peak concentrations were collected. The blood concentration of TAC was determined by enzyme immunoassay; CYP3A5 was genotyped by polymerase chain reaction-restriction fragment length polymorphism method; MYH9, LAMB2, ACTN4 and other genotypes were determined by MALDI-TOF MS method; PPK model was established by nonlinear mixed-effects method. Based on this, six machine learning algorithms, including eXtreme Gradient Boosting (XGBoost), Random Forest (RF), Extra-Trees, Gradient Boosting Decision Tree (GBDT), Adaptive boosting (AdaBoost) and Lasso, were used to establish the machine learning model of TAC clearance. Results: A one-compartment model of first-order absorption and elimination adequately described the pharmacokinetics of TAC. Age, co-administration of Wuzhi capsules, CYP3A5 *3/*3 genotype and CTLA4 rs4553808 genotype were significantly affecting the clearance of TAC. Among the six machine learning models, the Lasso algorithm model performed the best (R(2) = 0.42). Conclusion: For the first time, a clearance prediction model of TAC in pediatric patients with RNS was established using PPK combined with machine learning, by which the individual clearance of TAC can be predicted more accurately, and the initial dose of administration can be optimized to achieve the goal of individualized treatment. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9706003/ /pubmed/36457704 http://dx.doi.org/10.3389/fphar.2022.942129 Text en Copyright © 2022 Huang, Lin, Wang, Chen, Zheng, Zhong, Shang, Huang, Gao, Deng, Li, Zeng and Mo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Huang, Qiongbo Lin, Xiaobin Wang, Yang Chen, Xiujuan Zheng, Wei Zhong, Xiaoli Shang, Dewei Huang, Min Gao, Xia Deng, Hui Li, Jiali Zeng, Fangling Mo, Xiaolan Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title | Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title_full | Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title_fullStr | Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title_full_unstemmed | Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title_short | Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
title_sort | tacrolimus pharmacokinetics in pediatric nephrotic syndrome: a combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706003/ https://www.ncbi.nlm.nih.gov/pubmed/36457704 http://dx.doi.org/10.3389/fphar.2022.942129 |
work_keys_str_mv | AT huangqiongbo tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT linxiaobin tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT wangyang tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT chenxiujuan tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT zhengwei tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT zhongxiaoli tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT shangdewei tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT huangmin tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT gaoxia tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT denghui tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT lijiali tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT zengfangling tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction AT moxiaolan tacrolimuspharmacokineticsinpediatricnephroticsyndromeacombinationofpopulationpharmacokineticmodellingandmachinelearningapproachestoimproveindividualprediction |